Allurion Technologies, Inc. Research and Development Expense
Allurion Technologies, Inc. (ALUR) reported Research and Development Expense of $912.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-15
- Allurion Technologies, Inc. research and development expense for the quarter ending 2026-03-31 was $912.00K, a 65.24% decline year-over-year.
- Allurion Technologies, Inc. research and development expense for the quarter ending 2025-12-31 was $1.13M, a 72.56% decline year-over-year.
- Allurion Technologies, Inc. research and development expense for the quarter ending 2025-09-30 was $2.02M, a 37.24% decline year-over-year.
- Allurion Technologies, Inc. research and development expense for the quarter ending 2025-06-30 was $1.80M, a 58.24% decline year-over-year.
- Allurion Technologies, Inc. research and development expense for fiscal 2025 was $7.57M, a 56.41% decline from fiscal 2024.
- Allurion Technologies, Inc. research and development expense for fiscal 2024 was $17.37M, a 37.28% decline from fiscal 2023.
- Allurion Technologies, Inc. research and development expense for fiscal 2023 was $27.69M, a 63.23% increase from fiscal 2022.
- Allurion Technologies, Inc. research and development expense for fiscal 2022 was $16.97M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $912.00K 10-Q · filed 2026-05-15 | $2.04M derived: sum of 2 quarters · filed 2026-05-15 | $4.06M derived: sum of 3 quarters · filed 2026-05-15 | $5.86M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.15M derived: sum of 2 quarters · filed 2026-03-30 | $4.95M derived: sum of 3 quarters · filed 2026-03-30 | $7.57M 10-K · filed 2026-03-30 |
| 2025-09-30 | $2.02M 10-Q · filed 2025-11-17 | $3.82M derived: sum of 2 quarters · filed 2025-11-17 | $6.44M 10-Q · filed 2025-11-17 | $10.56M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-06-30 | $1.80M 10-Q · filed 2025-08-19 | $4.42M 10-Q · filed 2025-08-19 | $8.55M derived: sum of 3 quarters · filed 2026-05-15 | $11.76M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-03-31 | $2.62M 10-Q · filed 2026-05-15 | $6.75M derived: sum of 2 quarters · filed 2026-05-15 | $9.96M derived: sum of 3 quarters · filed 2026-05-15 | $14.27M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $7.33M derived: sum of 2 quarters · filed 2026-03-30 | $11.64M derived: sum of 3 quarters · filed 2026-03-30 | $17.37M 10-K · filed 2026-03-30 |
| 2024-09-30 | $3.21M 10-Q · filed 2025-11-17 | $7.52M derived: sum of 2 quarters · filed 2025-11-17 | $13.25M 10-Q · filed 2025-11-17 | $19.32M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | $4.31M 10-Q/A · filed 2025-08-28 | $10.04M 10-Q/A · filed 2025-08-28 | $16.11M derived: sum of 3 quarters · filed 2025-08-28 | $23.30M derived: sum of 4 quarters · filed 2025-08-28 |
| 2024-03-31 | $5.72M 10-Q/A · filed 2025-08-28 | $11.80M derived: sum of 2 quarters · filed 2025-08-28 | $18.99M derived: sum of 3 quarters · filed 2025-08-28 | $25.57M derived: sum of 4 quarters · filed 2025-08-28 |
| 2023-12-31 | $6.07M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2025-08-28 | $13.26M derived: sum of 2 quarters · filed 2025-08-28 | $19.84M derived: sum of 3 quarters · filed 2025-08-28 | $27.69M 10-K/A · filed 2025-08-28 |
| 2023-09-30 | $7.19M 10-Q/A · filed 2025-08-28 | $13.77M derived: sum of 2 quarters · filed 2025-08-28 | $21.62M 10-Q/A · filed 2025-08-28 | $27.36M derived: sum of 4 quarters · filed 2025-08-28 |
| 2023-06-30 | $6.58M 10-Q/A · filed 2025-08-28 | $14.43M 10-Q/A · filed 2025-08-28 | $20.16M derived: sum of 3 quarters · filed 2025-08-28 | $25.23M derived: sum of 4 quarters · filed 2025-08-28 |
| 2023-03-31 | $7.85M 10-Q/A · filed 2025-08-28 | $13.58M derived: sum of 2 quarters · filed 2025-08-28 | $18.65M derived: sum of 3 quarters · filed 2025-08-28 | $21.75M derived: sum of 4 quarters · filed 2025-08-28 |
| 2022-12-31 | $5.73M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-08-28 | $10.80M derived: sum of 2 quarters · filed 2025-08-28 | $13.90M derived: sum of 3 quarters · filed 2025-08-28 | $16.97M 10-K/A · filed 2025-08-28 |
| 2022-09-30 | $5.07M 10-Q · filed 2023-11-14 | $8.16M derived: sum of 2 quarters · filed 2023-11-14 | $11.23M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $3.10M 10-Q · filed 2023-10-20 | $6.17M 10-Q · filed 2023-10-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |
| NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | United States | $0.012B | |
| Sintx Technologies, Inc. (SINT) | United States | $0.012B | -1.10 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| CERENOME, INC. (CNSY) | United States | $0.014B | |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| SeaStar Medical Holding Corp (ICU) | United States | $0.015B | -1.14 |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B |